iCo Therapeutics Inc.
iCo Therapeutics Inc.
- ISIN: CA45107J1057
- Land: .
Nachricht vom 15.06.2017 | 22:15
iCo Therapeutics Announces Pre IND meeting for Novel Glaucoma Asset
DGAP-News: iCo Therapeutics Inc. / Key word(s): Miscellaneous
Vancouver, British Columbia--(Newsfile Corp. - June 15, 2017) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ('iCo' or 'the Company'), today reported it will hold a pre IND meeting with the Division of Transplantation and Ophthalmology, US Food and Drug Administration (FDA) on June 21st, 2017.
Stated Andrew Rae, CEO of iCo Therapeutics, 'we are excited to have arrived at this inflection point with our colleagues at Salvat and look forward to important guidance regarding a clinical path forward for a potential first in class glaucoma candidate'.
For more information please refer to:
Laboratorios SALVAT is a privately owned pharmaceutical group closely identified with technological innovation and strongly committed to R&D. SALVAT's headquartered are located in Barcelona (Spain) and its US subsidiary, SALVAT USA, is located in Miami, FL. Founded in 1955, SALVAT is present in over 60 countries and keeps strengthening its international presence through the licensing of its own developments. The company launched CETRAXAL® (ciprofloxacin 0.2 %) otic solution in the US in 2009 and received FDA approval for OTOVEL® (ciprofloxacin 0.3 % and fluocinolone acetonide 0.025 %) otic solution in April 2016.
Additional information regarding Laboratorios SALVAT and its products is available at www.salvatbiotech.com
About iCo Therapeutics
iCo Therapeutics identifies existing development stage assets for use in underserved ocular and infectious diseases. Such assets may exhibit utility in non-ophthalmic conditions outside the Company's core focus areas and if so the Company will seek to capture further value via partnerships, such as its partnership with Immune Pharmaceuticals (NASDAQ: IMNP), which is in several Phase 2 studies involving iCo-008. iCo shares trade on the TSX Venture Exchange under the symbol 'ICO' and on the OTCQB under the symbol 'ICOTF'.
For more information, visit the Company website at: www.icotherapeutics.com.
No regulatory authority has approved or disapproved the content of this press release. Neither the TSX Venture Exchange nor its Regulatory Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
Forward Looking Statements
Certain statements included in this press release may be considered forward-looking statements' within the meaning of applicable securities laws. Forward-looking statements can be identified by words such as: 'anticipate,' 'intend,' 'plan,' 'goal,' 'seek,' 'believe,' 'project,' 'estimate,' 'expect,' 'strategy,' 'future,' 'likely,' 'may,' 'should,' 'will,' and similar references to future periods. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on iCo's current beliefs as well as assumptions made by and information currently available to iCo and relate to, among other things, anticipated financial performance, business prospects, strategies, regulatory developments, market acceptance and future commitments. Readers are cautioned not to place undue reliance on these forward-looking statements, which are based only on information currently available to iCo and speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by iCo in its public securities filings and on its website, actual events may differ materially from current expectations. iCo disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Click on, or paste the following link into your web browser, to view the associated documents http://www.newsfilecorp.com/release/27456
|Company:||iCo Therapeutics Inc.|
|End of News||DGAP News Service|
GBC im Fokus
M1 Kliniken: Geschäftsjahr über den Erwartungen
Mit dem deutlichen Anstieg auf 21 Klinikstandorte (Ende 2016: 13) hat die auf ästhetische Medizin spezialisierte M1 Kliniken AG die Basis für einen Ausbau der Umsatz- und Ertragsbasis gelegt. Hinzu kommt die bereits in Umsetzung befindliche Erschließung weiterer Umsatzströme, wie etwa die Erweiterung der Eigenmarken oder die Abdeckung der ästhetischen Zahnmedizin. Das Kursziel beläuft sich auf 18,50 € und das Rating lautet KAUFEN.
Der AKTIONÄR News
22. Mai 09:40 Micron: Ungebremste Rallye nach 3 Top-News
18. Mai 2018
Original-Research: GBC Insider Focus Index (von GBC AG): GBC Insider Focus Index
21. Mai 2018